AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9130150 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracolumbar rotation measurement
Number of subjects: 55
Study 9130150 — intervention group
Group type: EXPERIMENTAL
Intervention: Between-rater reliability
Number of subjects: 55
Study 9130150 — intervention group
Group type: EXPERIMENTAL
Intervention: Within-rater reliability
Number of subjects: 55
Study 7959187 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric coated tablets
Number of subjects: 23
Study 7959187 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatin capsules
Number of subjects: 23
Study 3496848 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin, piperacillin, cefoperazone, and aztreonam administered intravenously for 9 days
Number of subjects: 20
Study 3496848 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 20
Study 3496848 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin and piperacillin
Number of subjects: 20
Study 29891250 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (2mg)
Number of subjects: 170
Study 29891250 — intervention group
Group type: COMPARATOR
Intervention: Saline (2mL)
Number of subjects: 170
Study 28554818 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 16
Study 28554818 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV in temperate conditions (22°C, 40% relative humidity)
Number of subjects: 16
Study 28554818 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV in hot-humid conditions (32°C, 70% relative humidity)
Number of subjects: 16
Study 28554818 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV use
Number of subjects: 16
Study 28554818 — intervention group
Group type: COMPARATOR
Intervention: No NIV
Number of subjects: 16
Study 25220555 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg intravenous)
Number of subjects: 53
Study 25220555 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl solution)
Number of subjects: 53
Study 23802352 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention A (weekly training courses with therapy sessions)
Number of subjects: 34
Study 23802352 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention B (modular and high structured small group training)
Number of subjects: 34
Study 23802352 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 34
Study 20812020 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 l PEG combined with 36 mg senna glycosides in tablets
Number of subjects: 490
Study 20812020 — intervention group
Group type: COMPARATOR
Intervention: 4 l PEG
Number of subjects: 490
Study 19929645 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site provision of implants and IUDs at Site B
Number of subjects: 62
Study 19929645 — intervention group
Group type: COMPARATOR
Intervention: Referral to public family planning services at Site A
Number of subjects: 62
Study 17134598 — intervention group
Group type: EXPERIMENTAL
Intervention: Issuing karyotype results on a prespecified fixed date
Number of subjects: 226
Study 17134598 — intervention group
Group type: COMPARATOR
Intervention: Issuing karyotype results as soon as they became available
Number of subjects: 226
Study 17134598 — intervention group
Group type: EXPERIMENTAL
Intervention: Issuing early results from a rapid molecular test for the most common chromosomal abnormalities
Number of subjects: 226
Study 17134598 — intervention group
Group type: COMPARATOR
Intervention: Receiving only the full karyotype results
Number of subjects: 226
Study 17134598 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety at the 1-month follow-up
Number of subjects: 226
Study 15255284 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg ospemifene
Number of subjects: 159
Study 15255284 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg ospemifene
Number of subjects: 159
Study 15255284 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg ospemifene
Number of subjects: 159
Study 15255284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 11750186 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (90 mg)
Number of subjects: 26
Study 11750186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 9259934 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral erythromycin for 7 days in addition to routine prophylactic intravenous ampicillin
Number of subjects: 51
Study 9259934 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin alone
Number of subjects: 51
Study 8315574 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine sensitivity (IC50 > 1 microM) in progressors
Number of subjects: 68
Study 8315574 — intervention group
Group type: EXPERIMENTAL
Intervention: Syncytium-inducing (SI) phenotype in progressors
Number of subjects: 68
Study 8315574 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine therapy
Number of subjects: 68
Study 8315574 — intervention group
Group type: EXPERIMENTAL
Intervention: SI phenotype
Number of subjects: 68
Study 3687352 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I: microaggregate‐poor erythrocyte concentrate (SAGM‐ERC) plus 3% dextran‐60 as plasma substitute, postoperative analgesia with intramuscular ketobemidone
Number of subjects: 45
Study 3687352 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II: microaggregate‐poor erythrocyte concentrate (SAGM‐ERC) plus 3% dextran‐60, prolonged epidural anesthesia with 0.5% bupivacaine
Number of subjects: 45
Study 3687352 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III: non‐frozen stored plasma plus SAGM‐ERC, postoperative analgesia with ketobemidone
Number of subjects: 45
Study 30391318 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO)
Number of subjects: 79
Study 30391318 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 79
Study 28422886 — intervention group
Group type: EXPERIMENTAL
Intervention: ETS at T2 level (group A)
Number of subjects: 50
Study 28422886 — intervention group
Group type: EXPERIMENTAL
Intervention: ETS at T3 level (group B)
Number of subjects: 50
Study 25936543 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping skills intervention
Number of subjects: 33
Study 25936543 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention
Number of subjects: 33
Study 25936543 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 33
Study 23638702 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 0
Study 20878293 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored print letters
Number of subjects: 1629
Study 20878293 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational telephone calls
Number of subjects: 1629
Study 20878293 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined tailored letters and motivational calls
Number of subjects: 1629
Study 20878293 — intervention group
Group type: COMPARATOR
Intervention: Control group (no information)
Number of subjects: 1629
Study 19955524 — intervention group
Group type: EXPERIMENTAL
Intervention: CT screening in round one
Number of subjects: 7557
Study 19955524 — intervention group
Group type: EXPERIMENTAL
Intervention: CT screening in round two
Number of subjects: 7557
Study 17445811 — intervention group
Group type: EXPERIMENTAL
Intervention: rFSH
Number of subjects: 66
Study 17445811 — intervention group
Group type: COMPARATOR
Intervention: CC
Number of subjects: 66
Study 17445811 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (CC and rFSH)
Number of subjects: 66
Study 15456082 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 1304
Study 15456082 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine
Number of subjects: 1304
Study 15456082 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynaecomastia resolution
Number of subjects: 1304
Study 15456082 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone levels
Number of subjects: 1304
Study 11178336 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptogramins (quinupristin/dalfopristin and RPR-106972)
Number of subjects: 0
Study 10207592 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime (2 g x 2/day) + Amikacin (7.5 mg.kg‐1 x 2/day)
Number of subjects: 275
Study 10207592 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (2 g x 3/day) + Amikacin (7.5 mg.kg‐1 x 2/day)
Number of subjects: 275
Study 10207592 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime + Amikacin
Number of subjects: 275
Study 10207592 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime + Amikacin
Number of subjects: 275
Study 8549245 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 Gy radiation therapy (single fraction)
Number of subjects: 40
Study 8549245 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 Gy radiation therapy
Number of subjects: 40
Study 8549245 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 Gy radiation therapy
Number of subjects: 40
Study 8549245 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 Gy radiation therapy
Number of subjects: 40
Study 8549245 — intervention group
Group type: COMPARATOR
Intervention: Natural history data of subfoveal age-related CNV
Number of subjects: 40
Study 2755259 — intervention group
Group type: EXPERIMENTAL
Intervention: Clebopride (0.5 mg/kg)
Number of subjects: 41
Study 2755259 — intervention group
Group type: EXPERIMENTAL
Intervention: Clebopride (0.75 mg/kg)
Number of subjects: 41
Study 2755259 — intervention group
Group type: EXPERIMENTAL
Intervention: Clebopride (1 mg/kg)
Number of subjects: 41
Study 2755259 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (10 mg/kg)
Number of subjects: 41
Study 2755259 — intervention group
Group type: EXPERIMENTAL
Intervention: Clebopride
Number of subjects: 41
Study 850063 — intervention group
Group type: EXPERIMENTAL
Intervention: Skill Training program
Number of subjects: 25
Study 850063 — intervention group
Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 25
Study 31638010 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (single dose 20 mg/kg, administered twice a year for 2 years)
Number of subjects: 0
Study 31638010 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of azithromycin (6 months apart)
Number of subjects: 0
Study 31638010 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of azithromycin
Number of subjects: 0
Study 31638010 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 doses of azithromycin
Number of subjects: 0
Study 31638010 — intervention group
Group type: COMPARATOR
Intervention: Original placebo group
Number of subjects: 0
Study 31638010 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin group
Number of subjects: 0
Study 31638010 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison
Number of subjects: 0
Study 27936524 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic clopidogrel product (75 mg once daily for 7 days)
Number of subjects: 32
Study 27936524 — intervention group
Group type: COMPARATOR
Intervention: Reference clopidogrel product (75 mg once daily for 7 days)
Number of subjects: 32
Study 26348588 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (psychoeducation plus medication)
Number of subjects: 61
Study 26348588 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (medication alone)
Number of subjects: 61
Study 23494740 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g of GaCr milk powder
Number of subjects: 66
Study 23494740 — intervention group
Group type: COMPARATOR
Intervention: Milk powder placebo
Number of subjects: 66
Study 22566310 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (0.5 g/kg/day for 5 days as continuous perfusion)
Number of subjects: 0
Study 22566310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18721167 — intervention group
Group type: EXPERIMENTAL
Intervention: WE*CAN intervention delivered during three routine clinic visits by trained 'Health Advisors' over an 8-month period; average of 2.85 intervention sessions.
Number of subjects: 122
Study 18721167 — intervention group
Group type: COMPARATOR
Intervention: Usual care comparison group (control group).
Number of subjects: 122
Study 18162017 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-g E-EPA
Number of subjects: 80
Study 18162017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 15077311 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg) at weeks 0, 2, and 6
Number of subjects: 103
Study 15077311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 11513820 — intervention group
Group type: EXPERIMENTAL
Intervention: Dawn simulation (1.5 hour dawn signal from 4:30 AM to 6:00 AM peaking at 250 lux)
Number of subjects: 95
Study 11513820 — intervention group
Group type: COMPARATOR
Intervention: Bright light therapy (10,000 lux for 30 min, from 6:00 AM to 6:30 AM)
Number of subjects: 95
Study 11513820 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dim red light, 1.5 hour dawn signal from 4:30 AM to 6:00 AM peaking at 0.5 lux)
Number of subjects: 95
Study 9742660 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ppm D4
Number of subjects: 0
Study 9742660 — intervention group
Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 0
Study 7828189 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of riboflavin as a single oral dose for at least 3 months
Number of subjects: 49
Study 7828189 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of riboflavin plus 75 mg of aspirin
Number of subjects: 49
Study 7828189 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 49
Study 2556883 — intervention group
Group type: EXPERIMENTAL
Intervention: RIT 4237 oral rotavirus vaccine
Number of subjects: 28
Study 1147073 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide
Number of subjects: 0
Study 1147073 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam
Number of subjects: 0
Study 1147073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30857413 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 8178
Study 30857413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8178
Study 30857413 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment
Number of subjects: 8178
Study 30857413 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure treatment
Number of subjects: 8178
Study 28475671 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib (dabrafenib 150 mg twice daily + trametinib 2 mg once daily)
Number of subjects: 423
Study 28475671 — intervention group
Group type: COMPARATOR
Intervention: Dabrafenib monotherapy
Number of subjects: 423
Study 28475671 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib
Number of subjects: 423
Study 26275039 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 1362
Study 23725524 — intervention group
Group type: EXPERIMENTAL
Intervention: Sour tea (ST)
Number of subjects: 100
Study 23725524 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea (GT)
Number of subjects: 100
Study 21355147 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion therapy
Number of subjects: 87
Study 21355147 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (Piracetam tablet)
Number of subjects: 87
Study 19041440 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (LD) OCP (30 mcg EE/150 mcg DSG)
Number of subjects: 0
Study 19041440 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low dose (VLD) OCP (20 mcg EE/150 mcg DSG)
Number of subjects: 0
Study 19041440 — intervention group
Group type: EXPERIMENTAL
Intervention: EE-only phase (10 mcg EE) in group VLD
Number of subjects: 0
Study 17953131 — intervention group
Group type: EXPERIMENTAL
Intervention: Drama therapy program
Number of subjects: 136
Study 17953131 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 136
Study 15372846 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe + statin
Number of subjects: 2382
Study 15372846 — intervention group
Group type: COMPARATOR
Intervention: statin
Number of subjects: 2382
Study 15372846 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2382
Study 15372846 — intervention group
Group type: COMPARATOR
Intervention: statin monotherapy (10, 20, 40 mg/day or 80 mg/day)
Number of subjects: 2382
Study 11552903 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide controlled ileal release 6 mg o.m.
Number of subjects: 143
Study 11552903 — intervention group
Group type: COMPARATOR
Intervention: Budesonide controlled ileal release flexible dosing (3, 6 or 9 mg o.m.)
Number of subjects: 143
Study 9589313 — intervention group
Group type: EXPERIMENTAL
Intervention: Ego threat (subliminal message)
Number of subjects: 60
Study 9589313 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical threat (subliminal message)
Number of subjects: 60
Study 9589313 — intervention group
Group type: COMPARATOR
Intervention: Neutral message (subliminal message)
Number of subjects: 60
Study 7522721 — intervention group
Group type: COMPARATOR
Intervention: Conventional salvage therapy
Number of subjects: 88
Study 7522721 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose chemotherapy with subsequent autologous bone marrow transplantation (HDC/ABMT)
Number of subjects: 88
Study 7522721 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation alone
Number of subjects: 88
Study 7522721 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term continuous complete remission (cCR) with salvage therapy
Number of subjects: 88
Study 3144299 — intervention group
Group type: EXPERIMENTAL
Intervention: +Oxyphenonium
Number of subjects: 8
Study 3144299 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic Oxyphenonium
Number of subjects: 8
Study 3144299 — intervention group
Group type: EXPERIMENTAL
Intervention: (-)Oxyphenonium
Number of subjects: 8
Study 3144299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31006920 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sleep deprivation
Number of subjects: 181
Study 31006920 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep (8–9 hr in bed)
Number of subjects: 181
Study 28135880 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR changes (G1)
Number of subjects: 3
Study 28135880 — intervention group
Group type: COMPARATOR
Intervention: Lecture, no changes in EHR (G2)
Number of subjects: 3
Study 28135880 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecture and EHR changes (G3)
Number of subjects: 3
Study 27450232 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19*3 (rs4986893) mutation
Number of subjects: 377
Study 27450232 — intervention group
Group type: EXPERIMENTAL
Intervention: CES1 rs8192950 mutation
Number of subjects: 377
Study 23468128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (0.5‐1 mg/week up to 3.0 mg/week) followed by ketoconazole (200 mg/day to 600 mg/day)
Number of subjects: 14
Study 23468128 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg/day to 600 mg/day) followed by cabergoline (0.5‐1 mg/week up to 3.0 mg/week)
Number of subjects: 14
Study 23468128 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched patients in prolonged remission after effective neurosurgery for CD)
Number of subjects: 14
Study 22763497 — intervention group
Group type: EXPERIMENTAL
Intervention: OTC analgesics
Number of subjects: 1734
Study 18930473 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial sleep deprivation therapy (six nights of total SD within three weeks, separated by nights of recovery sleep)
Number of subjects: 18
Study 18930473 — intervention group
Group type: COMPARATOR
Intervention: No sleep deprivation therapy (control group)
Number of subjects: 18
Study 17086382 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field (PEMF) therapy, 25 min per session, 5 days per week for 3 weeks.
Number of subjects: 46
Study 17086382 — intervention group
Group type: COMPARATOR
Intervention: Sham PEMF therapy, 25 min per session, 5 days per week for 3 weeks.
Number of subjects: 46
Study 15164859 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive interventions for children from divorced families
Number of subjects: 218
Study 15164859 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 218
Study 11593723 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.5 mg.kg‐1, orally, administered 45 min before induction) in Group M
Number of subjects: 109
Study 11593723 — intervention group
Group type: COMPARATOR
Intervention: Vehicle in Group C
Number of subjects: 109
Study 9589658 — intervention group
Group type: EXPERIMENTAL
Intervention: Human recombinant IL-6 (0.5 microgram/kg body weight)
Number of subjects: 16
Study 8051483 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-hydroxybutyrate during ischemic exercise (low-phosphate state)
Number of subjects: 17
Study 8051483 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-hydroxybutyrate during fructose-induced hepatic ATP breakdown (low-phosphate state)
Number of subjects: 17
Study 8051483 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-hydroxybutyrate during fructose-induced hepatic ATP breakdown (both phosphate conditions)
Number of subjects: 17
Study 2968548 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin (DTRp6-LH-RH) with human menopausal gonadotropin (long regimen)
Number of subjects: 30
Study 2968548 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin (DTRp6-LH-RH) with human menopausal gonadotropin (short regimen)
Number of subjects: 30
Study 2968548 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate-human menopausal gonadotropin combination without LH-RH analogue (control group)
Number of subjects: 30
Study 31545115 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-focused stress management intervention (four individual sessions with a community wellness coach over 3 months, supplemented with weekly text messaging and twice monthly group sessions for 6 months)
Number of subjects: 217
Study 31545115 — intervention group
Group type: COMPARATOR
Intervention: Standard care based on the guidelines of the National Institutes of Health
Number of subjects: 217
Study 30722059 — intervention group
Group type: EXPERIMENTAL
Intervention: Lefamulin 150 mg IV every 12 hours
Number of subjects: 551